Objective: IL-35 is a newly discovered immunoregulatory cytokine that possesses the ability to inhibit CD4 + effector T cells and alleviate autoimmune diseases. The objective of this study was to investigate IL-35 levels in patients with primary Sjogren's syndrome (pSS) and explore the roles of IL-35 in the pathogenesis of pSS. Methods: Thirty-four hospitalized patients with pSS were recruited, and 34 volunteers were enrolled as healthy controls. An ELISA was adopted to measure plasma IL-35 levels. The levels of P35 and EBI3 mRNAs in peripheral blood mononuclear cells (PBMCs) were determined using real-time quantitative PCR. 
| INTRODUCTION
Primary Sjogren's syndrome (pSS) is a typical autoimmune disease that predominantly affects middle-aged women. It is characterized by chronic inflammation and the reduced secretory function of the exocrine glands, particularly the lacrimal and salivary glands, resulting in dry-eye and dry-mouth symptoms. 1 Some patients also develop extraglandular manifestations, such as weakness and arthralgia. Patients with pSS have occult and a long disease course with no radical cure, which has seriously affected the quality of life of patients with pSS. As the second most common autoimmune disease, the incidence of pSS ranges from 3.1 to 10.7 cases per 100 000, 2 and the male-tofemale ratio is 1:20-1:9. 3 Although the exact pathogenesis of pSS remains elusive, many researchers have proposed Jie Guo and Mingli Gu Both authors contributed equally to this work that genetic and environmental factors cause the breakdown of immune tolerance to one's own glandular tissue, producing the autoimmune response and autoantibodies. 4 IL-35 is composed of Epstein-Barr virus-induced gene 3 (EBI3) and the p35 subunit of IL-12. 5 It is a new member of the IL-12 cytokine family that includes other three cytokines: IL-12, IL-23 and IL-27. The IL-12 cytokine family plays an important role in regulating T cell responses. 6 However, in contrast to the proinflammatory effects of other IL-12 family members (eg, 
| MATERIALS AND METHODS

| Participants
Thirty-four patients with pSS who were hospitalized in the Department of Rheumatology of the Changhai Hospital of the Second Military Medical University (Shanghai, China) were included in the present study. All patients' diagnoses were consistent with the guidelines developed by American-European consensus group (2002). 16 Exclusion criteria were as follows: (a) the presence of other autoimmune diseases; (b) a current infection; and (c) treatment with immunomodulatory therapy. We also selected 34 healthy volunteers as the control group. The study protocol was approved by the Ethics Board of Changhai Hospital of the Second Military Medical University, and was performed in accordance with the Declaration of Helsinki, and consent was obtained from all patients and healthy volunteers.
| Sample preparation
Plasma from all subjects was separated by centrifugation of EDTA anticoagulant-treated venous blood and stored at −80°C until testing. PBMCs were separated using FicollHypaque density gradient centrifugation. Total RNA was extracted using TRIzol and then reverse-transcribed to cDNAs according to the procedure of the Invitrogen reverse transcription kit, and cDNAs were stored at −80°C until further analysis. 
| Real-time quantitative PCR
PCR was performed on an ABI 7500 sequence detection system using a SYBR Green Real-time PCR kit. β-Actin was used as a control for normalization. Primers used for real-time PCR are shown in Table 2 .
| Flow cytometry analysis
Venous blood was collected using EDTA as an anticoagulant. This study used whole blood to stimulate lymphocytes. Whole blood (0.5 mL in 0.5 mL of RPMI 1640) was cultured (37°C, 5% CO 2 ) for 4.5 hours and stimulated with 10 μL of phorbol myristate acetate (PMA) (10 μg/mL), 2 μL of ionomycin (0.5 mg/mL; both from Sigma-Aldrich, St. Louis, MO) and 2 μL of Brefeldin A (GolgiPlug, BFA 5 mg/mL; BD Pharmingen, Franklin Lakes, NJ). Then, the cultured whole blood was collected and stained with an anti-CD4-PerCP antibody (eBioscience) and an anti-CD19-APC antibody (eBioscience). After the addition of rupturing agent and an RBC lysate, intracellular staining was performed with an anti-EBI3-PE antibody (eBioscience). The percentage of cytokine-secreting CD4 + EBI3 + T cells and CD19 + EBI3 + B cells was determined by flow cytometry using a FACSCalibur instrument (Becton Dickinson, Franklin Lakes, NJ).
| Data collection
The relevant clinical information and laboratory records were extracted from the medical records of patients with pSS, including the anti-SSA, anti-SSB, IgG, CRP, and ESR levels and ESSDAI score ( Table 1) . Measurements of IgG and CRP levels were performed according to the manufacturer's package inserts for Beckman Coulter reagents on the IMMAGE 800 analyser (Beckman Coulter, CA USA). Anti-SSA and anti-SSB titres in patients with pSS were determined using a EUROIMMUN ANA Profile 3 Euroline kit (EUROIMMUN AG, Lübeck, Germany), according to the manufacturer's instructions. ESR levels were detected using a Monitor-100 (Vital, Italy). ESSDAI scores were determined by the attending physicians. 3 | RESULTS
| Statistical analysis
| Plasma IL-35 levels were decreased in patients with pSS
We first detected the plasma IL-35 levels in patients with pSS and healthy controls. Patients with pSS presented with significantly lower plasma IL-35 levels (52.1 ± 14.6 pg/mL) than normal controls (127.1 ± 26.1 pg/mL, P < 0.001) (Figure 1 ).
| Decreased levels of the P35 and EBI3 mRNAs in patients with pSS
The expression of P35 and EBI3 mRNA was assayed in PBMCs from patients with pSS and healthy controls. The results are presented as the fold change in gene expression normalized to β-actin. As shown in Figure 2 , lower levels of the P35 (2.5 ± 0.9 vs 4.1 ± 0.5, P < 0.001) and EBI3 mRNAs (1.1 ± 0.5 vs 2.3 ± 0.8, P = 0.017) were detected in patients with pSS than in normal controls.
| Decreased CD4 + EBI3 + T cells but increased CD19 + EBI3 + B cells in patients with pSS
Next, the percentages of CD4 + EBI3 + T cells and CD19 + EBI3 + B cells in patients with pSS were analysed using flow cytometry. The percentage of CD4 + EBI3 + T cells was lower in patients with pSS than in healthy controls (1.1 ± 0.36 vs 3 ± 1.27, P < 0.001) (Figure 3 A, 
| Correlations with the clinical characteristics of patients with pSS
We calculated Spearman's correlation coefficients, and the plasma IL-35 levels and expression of the EBI3 mRNA were significantly correlated with the ESR levels and ESSDAI scores, and the percentage of CD4 + EBI3 + T cells correlated with the ESSDAI score (Table 3) . Moreover, we analysed the correlations between IL-35 levels, mRNA expression levels, percentages of CD4 + EBI3 + T cells, CD19 + EBI3 + B cells and anti-SSA and anti-SSB antibody statuses using the Mann-Whitney U test. Patients who were positive for anti-SSB levels presented with lower plasma IL-35 levels and percentages of CD4 + EBI3 + T cells (Table 4) .
| DISCUSSION
In the present study, significantly decreased plasma IL-35 levels were observed in patients with primary Sjogren's syndrome compared with healthy controls, and decreased plasma IL-35 levels were associated with high levels of ESR and ESSDAI scores in patients with pSS. Since its initial discovery in 2007, IL-35 has shown the ability to reduce the progression of inflammatory diseases and autoimmune diseases. 12 Altered Th17 and regulatory T cell ratios may play a pathogenic role by tipping the fine-tuned balance towards enhanced immune reactivity. 23 Therefore, we speculate that decreased IL-35 levels may facilitate the development of SS through the suppression of regulatory T cells and the expansion of Th17 cell development.
IL-35 is heterodimeric protein that covalently links EBI3 and the p35 subunit of IL-12. Based on our findings, the relative levels of both the P35 and EBI3 mRNAs were significantly decreased in patients with primary Sjogren's syndrome compared with healthy controls. EBI3 was first identified in B cells infected with Epstein-Barr virus; two members of the IL-12 family (IL-27 and IL-35) share the subunit EBI3. Both IL-27 and IL-35 are immunosuppressive cytokines. 24, 25 EBI3 is likely to negatively regulate the IL-17, IL-22 and Th17 transcription factor RORgt and inhibit the development of autoimmune diseases such as experimental colitis 5 and collagen-induced autoimmune arthritis. 26 The expression of the p35 subunit could promote the progression of herpes stromal keratitis (HSK) 27 and restrain liver fibrosis. 28 The two subunits of IL-35 have independent functions in regulating immunity and inflammation. When they interact to form the heterodimer, the p35 subunit may act as a ligand, whereas EBI3 is the key subunit required for the negative regulatory function of IL-35. 29 Moreover, strong negative correlations between EBI3 expression, but not the level of the p35, and the ESS-DAI score and ESR levels were observed in patients with pSS in the present study. EBI3 is a downstream target molecule of Foxp3. A reduction in the EBI3 level affects the regulation of Treg activity by Foxp3. 30 Regarding the autoantibodies, significantly lower plasma IL-35 levels and percentages of CD4 + EBI3 + T cells were observed in patients who were positive for anti-SSB antibodies than in patients with pSS who were negative for anti-SSB antibodies. This correlation was not observed for anti-SSA antibodies. According to previous reports, 31 ,32 the anti-SSB antibody exhibits relatively higher specificity. The association between anti-SSB antibodies and the percentage of CD4 + EBI3 + T cells may result from the higher specificity of anti-SSB antibodies. These results further confirmed that the EBI3 subunit plays an important role in the pathogenesis of SS.
In conclusion, the plasma IL-35 level, P35 and EBI3 mRNA expression levels and percentage of CD4 + EBI3 + T cells are dramatically decreased in patients with SS. IL-35 and EBI3 negatively correlated with ESR levels and the ESSDAI score, indicating that IL-35 levels are gauges of SS activity. Moreover, significantly lower IL-35 levels and percentages of CD4 + EBI3 + T cells were observed in patients with pSS who were positive for anti-SSB antibodies than patients who were negative for anti-SSB antibodies. Because of the low number of patients included or the heterogeneous presentation of SS, additional studies may be needed to confirm these preliminary results. Since IL-35 may be secreted exclusively by Treg cells and other cell populations with regulatory potential, it represents a novel potential target for the therapeutic manipulation of Treg activity to treat SS. Further studies are required to investigate the signal transduction mechanisms and the precise anti-inflammatory effect of IL-35 on SS, as well as to determine whether it represents a valid immunotherapeutic strategy for the treatment of SS.
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